ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line

CompletedOBSERVATIONAL
Enrollment

296

Participants

Timeline

Start Date

December 30, 2015

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Metastatic Colorectal Cancer
Trial Locations (31)

10126

Research Site, Torino

10153

Research Site, Torino

12100

Research Site, Confreria - Cuneo

17100

Research Site, Savona

18038

Research Site, Sanremo (IM)

21053

Research Site, Castellanza (VA)

25124

Research Site, Brescia

30035

Research Site, Mirano VE

44124

Research Site, Cona FE

53100

Research Site, Poggibonsi SI

61032

Research Site, Fano PU

67100

Research Site, L’Aquila

70013

Research Site, Castellana Grotte

71100

Research Site, Foggia

73100

Research Site, Lecce

74123

Research Site, Taranto

80020

Research Site, Frattamaggiore NA

80131

Research Site, Napoli

85028

Research Site, Rionero in Vulture (PZ)

85100

Research Site, Potenza

86170

Research Site, Isernia

90146

Research Site, Palermo

95123

Research Site, Catania

98039

Research Site, Taormina ME

Unknown

Research Site, Crema

00161

Research Site, Roma

00184

Research Site, Roma

00189

Research Site, Roma

00133

Research Site, Roma (RM)

03039

Research Site, Sora (FR)

01100

Research Site, Viterbo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT02624895 - ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line | Biotech Hunter | Biotech Hunter